Publications

The present section contains a select list of scientific publications on products and drug candidates in Zealand’s pipeline. The list is restricted to the past five years and includes titles of peer reviewed scientific journal publications and titles of oral as well as poster presentations given at scientific meetings.


Peptide therapeutics

Fosgerau, K. and Hoffmann, T.
Peptide therapeutics: current status and future directions
Drug Discovery Today, 2014

Steensberg, A. and Simons, Tad D.
Beyond biomarkers in drug discovery and development
Drug Discovery Today, 2014


Glepaglutide

Naimi, R.M., et al
Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial.
Article, The Lancet Gastroenterology & Hepatology, 2019

Naimi, R.M., Hvistendahl, M., Groenbaek, H., Vilstrup, H., Moeller, H.J., and Jeppesen, P.B.
Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analog, on activation of liver macrophages and gut integrity in patients with short bowel syndrome.
Poster, Digestive Disease Week, San Diego, 2019

Hvistendahl, M., Naimi, R.M., Hansen, S.H., Kissow, H., Pedersen, J., Dragsted, L.O., and Jeppesen, P.B.
Glepaglutide, a novel long-acting glucagon-like peptide-2 analog, ameliorates distrubances in gut-liver axis by triggering farnesoid X receptor signaling pathways inpatients with short bowel syndrome.
Poster, ASPEN Nutrition Science & Practice Conference, Phoenix, 2019

Naimi, R.M., Hvistendahl, M., Holst, J.J., Hartmann, B., Hansen, M.B., and Jeppesen, P.B.
Glepaglutide, a long-acting glucagon-like peptide-2 analog, alters postprandial intestinal hormone levels but not glucose homeostasis in patients with short bowel syndrome.
Poster, 40th ESPEN Conference, Madrid, 2018

Hvistendahl, M., Naimi, R.M., Nerup, N.A., Ambrus, R.B., Ring, L.L., Achiam, M.P., Svendsen, L.B., Hansen, M.B., and Jeppesen, P.B.
Effects of glepaglutide, a long-acting glucagon-like peptide-2 analog, on hepatic function as measured by transient elastography and indocyanine green clearance in patients with short bowel syndrome.
Poster, 40th ESPEN Conference, Madrid, 2018.

Naimi, R.M., Hvistendahl, M., Poulsen, S.S., Kissow, H., Andreasen, R.H., Hansen, M.B., and Jeppesen, P.B.
Effects of short-term treatment with glepaglutide, a novel long-acting glucagon-like peptide-2 analog, on intestinal morphology and citrulline in patients with short bowel syndrome.
Presentation (Abstract), Digestive Disease Week, Washington, D.C., 2018

Hvistendahl, M., Naimi, R.M., Enevoldsen, L.H., Madsen, J.L., Fuglsang, S., Hansen, M.B., and Jeppesen, P.B.
Glepaglutide, a glucagon-like peptide-2 analog, ameliorates accelerated gastrointestinal transit time in patients with short bowel syndrome.
Poster, Digestive Disease Week, Washington, D.C., 2018

Hvistendahl, M., Naimi, R.M., Hansen, M.B., and Jeppesen, P.B.
Glepaglutide, a novel long-acting glucagon-like peptide-2 analog, improves intestinal absorption of macronutrients, body weight and lean body mass in patients with short bowel syndrome.
Presentation (Abstract), Digestive Disease Week, Washington, D.C., 2018

Naimi, R.M., Hvistendahl, M., Hansen, M.B., and Jeppesen, P.B.
Dose-dependent effects of glepaglutide, a long-acting glucagon-like peptide-2 analog, on fecal output in patients with short bowel syndrome
Presentation (Abstract), ASPEN Nutrition Science & Practice Conference, Las Vegas, 2018

Pre-clinical

Skarbaliene, J., Thorkildsen, C., Petersen, Y.M., Berner-Hansen, M., Russell, W.S.
Therapeutic potential of GLP-2 receptor agonist glepaglutide in a rat model of recurrent indomethacin-induced small intestinal inflammation
Poster, 40th ESPEN Conference, Madrid, 2018

Glerup, P., Sonne, K., Russell, W., Walton, C., Chesher, C.
Intestinotrophic effects of glepaglutide following chronic exposure in rats and dogs
Poster, UEG Week, Austria, Vienna, 2018


Stable glucagon analog

Sabrina Lyngbye Wendt, Carsten Boye Knudsen, John Bagterp Jørgensen, Henrik Madsen, Ahmad Haidar
Modelling the glucose-insulin-glucagon dynamics after subcutaneous administration of native glucagon and a novel glucagon analog in dogs.
ATTD (Advanced Technologies and Treatments for Diabetes), Milan, 3-6 February 2016

Sabrina Lyngbye Wendt, Anders Valeur, Henrik Madsen, John Bagterp Jørgensen, Carsten Boye Knudsen
Pharmacokinetics modeling of glucagon and a novel glucagon analog after subcutaneous administration in dogs.
ATTD (Advanced Technologies and Treatments for Diabetes), Paris, 18-21 February 2015

Noerregaard, P., Valeur, A., Svendgaard, M., Giehm, L., Macchi, F., Fosgerau, K. and Riber, D.
The novel glucagon analog ZP-GA-1 has superior physicochemical properties while maintaining the pharmacokinetic and pharmacodynamic profile of native glucagon.
Poster, the American Diabetes Association’s (ADA) 74th Scientific Sessions, San Francisco, USA, June 13-17, 2014

Riber, D., Valeur, A., Svendgaard, M., Giehm, L., Macchi, F., Fosgerau, K. and Noerregaard, P.
The novel glucagon analog ZP-GA-1 has superior physicochemical properties while maintaining the pharmacokinetic and pharmacodynamic profile of native glucagon
Abstract, the American Diabetes Association’s (ADA) 74th Scientific Sessions, San Francisco, USA, June 13-17, 2014


Glucagon analog for liquid formulation

Sabrina L. Wendt, Jan K. Møller, Ahmad Haidar, Britta V. Bysted, Carsten B. Knudsen, Henrik Madsen, John B. Jørgensen
Model of the Glucose-Insulin-Glucagon Dynamics after Subcutaneous Administration of a Glucagon Rescue Bolus in Healthy Humans
Poster, the American Diabetes Association’s (ADA) 76th Scientific Sessions, New Orleans, USA, June 10-14, 2016

Noerregaard, P., Valeur, A., Svendgaard, M., Giehm, L., Macchi, F., Fosgerau, K. and Riber, D.
The novel glucagon analog ZP-GA-1 has superior physicochemical properties while maintaining the pharmacokinetic and pharmacodynamic profile of native glucagon 
Poster, the American Diabetes Association’s (ADA) 74th Scientific Sessions, San Francisco, USA, June 13-17, 2014

Riber, D., Valeur, A., Svendgaard, M., Giehm, L., Macchi, F., Fosgerau, K. and Noerregaard, P.
The novel glucagon analog ZP-GA-1 has superior physicochemical properties while maintaining the pharmacokinetic and pharmacodynamic profile of native glucagon 
Abstract, the American Diabetes Association’s (ADA) 74th Scientific Sessions, San Francisco, USA, June 13-17, 2014


GLP-1/GLP-2 dual agonist

Just, R.
The novel GLP-1-GLP-2 dual agonist ZP-GG-72 increases intestinal growth and improves insulin sensitivity in DIO mice
Oral presentation, the American Diabetes Association’s (ADA) 74th Scientific Sessions, San Francisco, USA, June 13-17, 2014

Russell, W.S., Riber, D., Fog, J.U., Fosgerau, K. and Just, R.
The novel GLP-1-GLP-2 dual agonist ZP-GG-72 increases intestinal growth and improves insulin sensitivity in DIO mice
Abstract, the American Diabetes Association’s (ADA) 74th Scientific Sessions, San Francisco, USA, June 13-17, 2014


GLP-1/GIP receptor dual agonist

Pia Noerregaard, Maria A. Deryabina, Jacob U. Fog, Pernille T. Shelton, Lise Giehm, and Jens R. Daugaard.
A novel gip receptor agonist enhances the body weight lowering effect of liraglutide in diet-induced obese mice and has the potential for once-weekly administration in humans.
Poster, EASD, September 14-18 2015

Carsten Boye Knudsen, Jens Rosengren Daugaard, Pernille Tofteng Shelton, Lise Giehm, Maria A. Deryabina, Jacob Ulrik Fog and Pia Noerregaard
An optimized novel GLP-1-GIP receptor dual agonist with potent effects on body weight and glucose control in mice has the potential for once-weekly administration in humans.
Poster, the American Diabetes Association’s (ADA) 75th Scientific Sessions, Boston, USA, June 5 – 9 2015

Maria A. Deryabina, Jens Rosengren Daugaard, Carsten Boye Knudsen, Pernille Tofteng Shelton, Jacob Ulrik Fog, Lene Jessen, and Pia Noerregaard
Pharmacokinetics and pharmacodynamics of GLP-1-GIP receptor dual agonist peptides: from once-daily to once-weekly
Poster, the American Diabetes Association’s (ADA) 75th Scientific Sessions, Boston, USA, June 5 – 9 2015


GLP-1/Gastrin dual acting receptor agonist program

Jolanta Skarbalienea, Thomas Secherb, Jacob Jelsing, Ansarullahc, Trine S.R. Neerupa, Nils Billestrupd, Keld Fosgerau
The anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF rats
Article, Peptides 69 (2015) 47–55

Jolanta Skarbaliene, Kristoffer T.G. Rigbolt, Nils Billestrup, and Keld Fosgerau
Effect of GLP-1-Gastrin Dual Agonist ZP3022 on Pancreas Gene Expression in ZDF Rats
Poster, the American Diabetes Association’s (ADA) 75th Scientific Sessions, Boston, USA, June 5 – 9 2015

Dalbøge, L.S., D., L. C. Almholt, Neerup, T.S.R., Neerup, Vrang, N., Jelsing, J., Fosgerau, K.
The novel GLP-1-gastrin dual agonist ZP3022 improves glucose homeostasis and increases β-cell mass without affecting islet number in db/db mice.
Article, J Pharmacol Exp Ther. August 2014, 350(2):353-60